MEI Pharma, Inc. (MEIP)
NASDAQ$2.309
Market Cap
$15.38M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
706 of 924
Rank in Industry
402 of 527
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
MEIP Insider Trading Activity
MEIP Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $0 | 0 | – |
Sells | $0 | 0 | – |
Related Transactions
No records found
About MEI Pharma, Inc.
MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase III clinical trial for the treatment of patients with relapsed/refractory follicular lymphoma, as well as in Phase Ib multi-arm trial to treat B-cell malignancies; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase Ib clinical trial for acute myeloid leukemia and …
Insider Activity of MEI Pharma, Inc.
Over the last 12 months, insiders at MEI Pharma, Inc. have bought $0 and sold $0 worth of MEI Pharma, Inc. stock.
On average, over the past 5 years, insiders at MEI Pharma, Inc. have bought $1.07M and sold $100,625 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 48,060 shares for transaction amount of $329,331 was made by Anson Funds Management LP (10 percent owner) on 2023‑09‑22.
List of Insider Buy and Sell Transactions, MEI Pharma, Inc.
| 2023-09-22 | Anson Funds Management LP | 10 percent owner | 48,060 0.6547% | $6.85 | $329,331 | -34.64% | ||
| 2023-09-22 | Funicular Funds, LP | 10 percent owner | 32,040 0.4364% | $6.85 | $219,554 | -34.64% | ||
| 2023-09-21 | Anson Funds Management LP | 10 percent owner | 33,600 0.4922% | $6.46 | $217,110 | -25.49% | ||
| 2023-09-21 | Funicular Funds, LP | 10 percent owner | 22,400 0.3281% | $6.46 | $144,740 | -25.49% | ||
| 2023-09-20 | Anson Funds Management LP | 10 percent owner | 120,000 1.7317% | $6.01 | $721,116 | -20.72% | ||
| 2023-09-20 | Funicular Funds, LP | 10 percent owner | 80,000 1.1544% | $6.01 | $480,744 | -20.72% | ||
| 2023-02-28 | Baltic Charles V. III | director | 81,500 0.0619% | $0.23 | $18,338 | +54.68% | ||
| 2021-02-23 | Sale | DRISCOLL FREDERICK W | director | 25,000 0.0011% | $4.03 | $100,625 | -29.33% | |
| 2019-12-19 | GOLD DANIEL P PHD | Chief Executive Officer | 18,750 0.0011% | $1.60 | $30,000 | +54.47% | ||
| 2019-12-19 | DRISCOLL FREDERICK W | director | 62,500 0.0035% | $1.60 | $100,000 | +54.47% | ||
| 2019-12-19 | Drazba Brian G. | Chief Financial Officer | 12,500 0.0007% | $1.60 | $20,000 | +54.47% | ||
| 2019-12-19 | Reynolds Thomas C | director | 10,000 0.0006% | $1.60 | $16,000 | +54.47% | ||
| 2019-09-06 | White Christine Anna | director | 15,000 0.001% | $1.74 | $26,075 | +32.37% | ||
| 2018-08-07 | Sale | Urso David M | Chief Operating Officer & GC | 9,500 0.0007% | $3.58 | $34,044 | -17.86% | |
| 2017-11-27 | Sale | Baltic Charles V. III | director | 11,000 0.0015% | $2.21 | $24,272 | +38.58% | |
| 2017-11-27 | Baltic Charles V. III | director | 11,000 0.0015% | $2.25 | $24,801 | +38.58% | ||
| 2015-11-09 | Sale | VIVO VENTURES VII, LLC | 10 percent owner | 314,704 0.0465% | $1.75 | $550,732 | -15.68% | |
| 2015-11-09 | Sale | Vivo Ventures V, LLC | 10 percent owner | 18,284 0.0027% | $1.75 | $31,997 | -15.68% | |
| 2015-11-06 | Sale | VIVO VENTURES VII, LLC | 10 percent owner | 15,120 0.0023% | $1.85 | $27,972 | -19.56% | |
| 2015-11-06 | Sale | Vivo Ventures V, LLC | 10 percent owner | 880 0.0001% | $1.85 | $1,628 | -19.56% |
Total: 67
Insider Historical Profitability
16.69%
| NOVOGEN LTD | 10 percent owner | 52408295 786.5735% | $121.01M | 1 | 0 | |
| Anson Funds Management LP | 10 percent owner | 864188 12.9702% | $2M | 3 | 0 | <0.0001% |
| Funicular Funds, LP | 10 percent owner | 460840 6.9165% | $1.06M | 3 | 0 | <0.0001% |
| GOLD DANIEL P PHD | Chief Executive Officer | 361632 5.4276% | $835,008.29 | 1 | 0 | +54.47% |
| Baltic Charles V. III | director | 105750 1.5872% | $244,176.75 | 10 | 1 | +32.53% |
Historical Insider Profitability vs. Competitors
$8,900,811 | 57 | -24.79% | $15.15M | |
$85,897,100 | 36 | 2.47% | $17.01M | |
$217,684 | 34 | 1.61% | $17.89M | |
$4,368,362 | 28 | -22.35% | $14.54M | |
$550,893 | 22 | -22.12% | $15M |
MEIP Institutional Investors: Active Positions
| Increased Positions | 12 | +30.77% | 95,015 | +3.47% |
| Decreased Positions | 13 | -33.33% | 131,490 | -4.8% |
| New Positions | 8 | New | 73,202 | New |
| Sold Out Positions | 6 | Sold Out | 93,990 | Sold Out |
| Total Postitions | 38 | -2.56% | 3M | -1.33% |
MEIP Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| Anson Funds Management Lp | $2,799.00 | 15.62% | 1.09M | +<1 | 0% | 2024-12-31 |
| Cable Car Capital, Lp | $1,565.00 | 8.74% | 611,440 | 0 | 0% | 2024-12-31 |
| Vanguard Group Inc | $987.00 | 5.51% | 385,728 | 0 | 0% | 2024-12-31 |
| Renaissance Technologies Llc | $345.00 | 1.93% | 134,946 | -2,700 | -1.96% | 2024-12-31 |
| Acadian Asset Management Llc | $259.00 | 1.45% | 101,313 | -31,049 | -23.46% | 2024-12-31 |
| Blackrock, Inc. | $170.00 | 0.95% | 66,506 | -754 | -1.12% | 2024-12-31 |
| Geode Capital Management, Llc | $152.00 | 0.85% | 59,207 | -95 | -0.16% | 2024-12-31 |
| Citadel Advisors Llc | $94.00 | 0.52% | 36,665 | +36,665 | New | 2024-12-31 |
| Northern Trust Corp | $91.00 | 0.51% | 35,596 | +12,561 | +54.53% | 2024-12-31 |
| Macquarie Group Ltd | $77.00 | 0.43% | 29,999 | 0 | 0% | 2024-12-31 |
Financial Ratios
Summary
Comparison with Competitors
Analyst Recommendations
Analyst Price Targets
No data is available at this moment.
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.